论文部分内容阅读
人类乙型肝炎是一个世界性公共健康问题。目前对于本病尚未有有效的治疗方法。因此,预防疾病的发生是最主要的。据统计,目前在世界上大约有1.5～2亿乙型肝炎病毒(HBV)携带者。这些携带者中的25%将死于肝硬化和/或肝细胞癌(HCC)。从1980年至1981年间通过临床试用证实乙型肝炎血源疫苗(简称血源疫苗)对预防 HBV感染是安全有效的。但由于此疫苗费用昂贵以及来源困难,因而其广泛应用受到限制。随着近代分子遗传学和核酸化学研究的进展,使人们能对生物活性物质中的基因密码进行分析。同时在人工调控下可使遗传物质在细胞间传递,并以蛋白质的形式表达出来,DNA 重组技术已用于使乙型肝炎病毒
Human Hepatitis B is a worldwide public health problem. Currently there is no effective treatment for this disease. Therefore, the prevention of disease is the most important. According to statistics, there are about 1.5 to 200 million Hepatitis B virus carriers in the world at present. 25% of these carriers will die of cirrhosis and / or hepatocellular carcinoma (HCC). From 1980 to 1981 through clinical trials confirmed that hepatitis B blood vaccine (referred to as blood-borne vaccine) is safe and effective in the prevention of HBV infection. However, due to its high cost and difficult source of supply, its widespread use is limited. With the development of modern molecular genetics and nucleic acid chemistry, people can analyze the genetic code of bioactive substances. At the same time, under artificial control, genetic material can be transmitted between cells and expressed in the form of protein. Recombinant DNA technology has been used to make hepatitis B virus